Medical Cannabis Education
Increasing patient access to medical cannabis
through the education of physicians worldwide.
Comprehensive & locally tailored training of prescribers including clinical guidelines for relevant pathologies.
Harnessing the power of education to support regulatory developments and equip stakeholders with know-how.
Knowledge itself is Power.
Medical Cannabis Education
We believe that education is at the core of truly increasing access to medical cannabis for patients around the world. Through education we are fighting stigma’s and preconceived notions surrounding cannabis and equipping healthcare professionals with the skills required to work with cannabinoids.
Education is a key component of effective commercial strategies. Providing healthcare professionals who are inexperienced in the use of cannabinoids, the knowledge and tools they need to begin prescribing with confidence leads to long lasting relationships based on trust.
Early education of industry stakeholders is important in developing medical cannabis markets around the world. Expedite adoption by physicians through training on the use of cananbinoids to treat various pathologies. This is our way of increasing access to medical cannabis for patients.
Principles of Clinical Cannabinology
This publication, co-authored by Cannabiscientia SA and Prohibition Partners, is intended to be of support to the European healthcare professional, and all those interested in understanding the medical use of cannabis in Europe, merging in one single textbook a comprehensive overview of the science, regulations, medicine and products on the market.
Topics covered include the physiology of the endocannabinoid system, the pharmacology of cannabis and its clinical relevance for a number of pathologies. The handbook also includes case studies and practical evidence of experienced prescribers around the globe that can serve as a guiding support in the obstacles of translating theory to practical applications.
“One of the reasons that pushes me to strive to educate as many HCPs as possible, is that currently, in the countries where MC is available through prescription, the majority of those are still running through the private system – meaning that all costs are on the patient.
It also means that if there isn’t an effort to harmonise the integration of cannabis as a medical therapy with National Healthcare Systems and and healthcare insurances, the chances are very little for a medical market to not be substituted by an industry that is completely different, that of consumer goods – aka cannabis sold within an adult-use market.”